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Abstract 
 
 Patients diagnosed with high grade glioma have a short life expectancy due to 
rapid progression of disease following and/or during treatment. Magnetic resonance 
imaging (MRI) is the primary method of surveying tumor progression, but is costly, 
lengthy in duration and often uncomfortable for the patient. An alternative to MRI that is 
cost efficient and patient friendly is of great interest to the medical community. If this 
alternative could also provide advanced notification of disease progression, then this 
patient population would have the opportunity for earlier treatment and the potential for 
greater efficacy. To pursue this concept, we assessed whether the Montreal Cognitive 
Assessment (MoCA) could be that MRI alternative, potentially providing an early 
identifier of disease progression for the high grade glioma population. We 
retrospectively assessed a variety of medical and surgical data points, in conjunction 
with the MoCA scores for individuals with a high grade glioma diagnosis who received 
surgery and/or biopsy with radiation treatment and had at least one instance of disease 
progression. Of the 128 subjects intended to fulfill our sample size requirement, only 5 
subjects qualified for enrollment. Our statistical tests were greatly impacted by this 
unfortunate circumstance and because of this we were not able to support the MoCA as 
hypothesized because the results did not reach the level of statistical significance. We 
have identified many interesting trends, but without an appropriate sample size these 
cannot be validated.  We hope the study concept and design will provide the basis for 
future research that can build upon our hypothesis and provide a definite answer.  
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Chapter 1 Introduction 
 
Introduction 
 High grade glioma is one of the most aggressive forms of brain cancer. Glioma 
refers to any tumor that is derived from a cell type within the brain known as a glial cell. 
Glial cells are the most bountiful cell type within the central nervous system. They 
surround, insulate and provide support to neurons, the basic unit of the brain. The 
abnormal growth of these cells can lead to the formation of gliomas, some being benign 
and others malignant. The most severe forms of the malignant glioma, that also pose 
the most significant threat, are called high grade. Within the United States, the annual 
incidence of new high grade glioma diagnoses is 14,000, which is roughly 5 cases per 
100,000 people (1). High grade glioma patients have a very poor prognosis, and those 
with the most common type of high grade glioma, a glioblastoma, have a median 
survival time of only 14.6 months even with standard treatment (2).  
 
The troubling reality with regard to treatment options for high grade glioma 
patients is that it is lagging behind many other areas of oncology due to the delicate and 
complex nature of the brain. Current standard of care involves maximally safe surgical 
resection followed by radiation and chemotherapy. These modalities have limitations in 
the brain, which present unique challenges related to morbidity associated with brain 
surgery and altered brain penetration of chemotherapeutic agents due to the blood brain 
barrier. Currently, there are many clinical trials researching alternative, more efficacious 
treatments. 
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The typical first step in therapy following diagnosis is to surgically remove as 
much tumor as feasibly possible without damaging the healthy brain. This would be 
followed by post-operative radiographic imaging, typically a magnetic resonance 
imaging (MRI) scan of the brain to serve as a baseline for future imaging comparisons. 
This is typically performed within 72 hours of surgery to best determine the extent of 
resection. Radiation begins 4 weeks after resection, delivering 60 cGy 5 days a week 
for 6 weeks. Repeat MRI of the brain is performed 3-4 weeks after completion of 
radiation for reassessment. Chemotherapy is typically given concurrently with radiation 
due to its ability to provide radio-sensitization. Adjuvant chemotherapy following 
completion of radiation is often offered as well. Despite this treatment, high grade 
gliomas are thought to be incurable tumors with the expectation of progressive disease 
at some point following treatment (3). 
 
Ideally, early detection of tumor progression could allow for the ability to start 
treatment earlier, thus leading to greater efficacy and a potential delay or avoidance in 
quality of life decline. Surveillance is typically achieved through MRI scans as frequently 
as every 2-3 months. In rare instances where MRI may be contraindicated, 
computerized tomography (CT) scans may substitute as the medium for radiographic 
imaging. MRI comes with many inconveniences to the patient such as high cost, a 
somewhat lengthy appointment and discomfort brought on by loud noise and a confined 
space, so alternative surveillance methods would be a welcomed addition to the 
standard care for these patients. 
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Due to the fact that high grade gliomas wreak havoc on the control center of the 
human body, these patients can experience decline in many ways, but what is most 
noticeable, especially to close friends and family, is a decline in cognitive function. This 
can be a very disheartening thing to witness as it can deteriorate a person’s mind to the 
point where a loved one can seem unrecognizable. Perhaps this symptom can be used 
to the patient’s advantage in that cognitive function and its decline over time can be 
measured quantitatively through a variety of validated assessment tools. This raises the 
question of whether one of these cognitive assessment tools could be used to identify 
clinical progression in these high grade glioma patients. 
 
One such tool with a great deal of potential due to its quick, easy and 
comprehensive nature is called the Montreal Cognitive Assessment (MoCA). The MoCA 
is routinely used in the neuro-oncology clinical setting at the Spectrum Health Brain and 
Spine Tumor Center in Grand Rapids, Michigan in an effort to quantify cognitive decline 
in patients with brain tumors. Because cognitive decline is a commonly known side 
effect of brain tumors such as high grade gliomas, utilizing metrics from these MoCAs 
may provide some insight on tumor progression.  
 
Some very promising research was published in 2003 that investigated the use of 
a battery of cognitive assessment tools on 56 patients with recurrent brain tumors. The 
results demonstrated that a decline in brain function could be detected approximately 6 
weeks prior to radiographic evidence of tumor progression in these patients (4). If the 
results of this study can be confirmed, then identifying and quantifying cognitive decline 
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in advance of tumor progression could be a huge step forward for the high grade glioma 
community. The battery of cognitive assessment tools used in this research did not 
include the MoCA nor has the MoCA been used in a fashion similar to the study’s 
design, but if a comparable study focusing on high grade glioma patients were to 
display similar results using the MoCA, it may prove to be a reliable indicator of disease 
progression for this population with an abbreviated battery that is more quickly and 
easily administered.  
 
Purpose  
The purpose of this study is to evaluate whether the MoCA could be adopted as 
a reliable, early identifier of disease progression in the high grade glioma population and 
thereby limit the burden of radiographic imaging. 
 
Specific Aim 1: Determine whether there is a statistically significant decline in 
MoCA scores from a predetermined baseline to disease progression.   
 
Specific Aim 2: Determine the average time point between baseline and disease 
progression where MoCA scores see the largest magnitude of change between 
consecutive assessments.  
 
Significance 
If the anticipated outcomes of our research are confirmed and other future 
research within the neuro-oncology community validates our results, MoCAs could 
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become a universally accepted standard practice within neuro-oncology clinics around 
the country and possibly the world. At worst, in instances where radiographic evidence 
of disease progression is questionable, a MoCA would be able to provide a valid second 
method of diagnosis. More impressively, MoCAs have the potential to reduce the 
frequency of radiographic imaging and all the unfavorable consequences associated 
with radiographic imaging, such as time, expense, patient anxiety/discomfort and even 
radiation exposure when receiving a CT scan. If MoCAs do provide reliable early 
identification of high grade glioma disease progression, then the opportunity exists for 
physicians to provide early treatment. For a population with such a poor prognosis and 
limited quality of life, any advances in care would make a big difference when viewed 
from the patient’s perspective.  
 
  
 16 
Chapter 2 Review of Literature 
 
Current Practices 
Assessing patients for mild cognitive impairment is an elusive goal because there 
are no definitive diagnostic tests to objectively measure cognitive function. In addition, 
there is rarely a “normal” baseline measure of cognition available for a given patient that 
can be used in comparison with later assessments of cognitive function and potential 
decline. The current gold standard for diagnosis of cognitive impairment is the patient’s 
clinical history, with corroboration from an informant. The clinician’s collection of the 
patient’s history and assessment should consistently use a combination of 
neuropsychological examinations, laboratory results (to exclude any other etiologies) 
and appropriate brain imaging (5). Although, neuropsychological testing alone cannot 
establish a diagnosis, it does contribute very useful information for quantifying cognitive 
decline. There is no single cognitive assessment tool recognized as the premier tool of 
choice, but the Alzheimer’s Association does recommend the General Practitioner 
Assessment of Cognition (GPCOG), Mini-Cog and Memory Impairment Screen (MIS) 
based primarily on these tools’ ease of use within the clinical setting and their 
equivalence or superiority to the commonly used Mini-Mental State Exam (MMSE) (6).  
 
Clinicians typically prefer to use cognitive assessment tools that are short in 
length and easily administered within the office setting to not only examine cognitive 
deterioration over time, but also to identify whether a more comprehensive cognitive 
evaluation should be performed by a trained neuropsychologist. While conditions such 
as Alzheimer’s, Parkinson’s and dementia have the luxury of a slower rate of cognitive 
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decline during which changes can be assessed on a yearly basis, patients with an 
aggressive brain cancer can experience a much more rapid decline. Because of the 
progressive nature of brain cancers, progressing often over months, clinicians caring for 
these patients prefer a more frequent and less intense regimen of cognitive testing to 
accommodate a patient population that does not necessarily have time at its disposal.  
 
Montreal Cognitive Assessment 
The MoCA is a comprehensive cognitive screening test developed by Dr. Ziad 
Nasreddine, a neurologist who graduated from the University of Sherbrooke (Quebec) 
and completed his fellowship at the University of California, Los Angeles. Dr. 
Nasreddine’s goal was to develop a quick, easy and comprehensive cognitive screening 
that is precise, specific and sensitive for use by clinicians of high volume, first line 
specialty clinics. 
 
The MoCA was first validated in 2000 when it showed excellent performance in 
distinguishing between cognitively intact and impaired groups classified by a gold 
standard neuropsychological assessment (7). Another validation study occurred 
between 2003 and 2004, which confirmed the test’s ability to distinguish normal controls 
from subjects with mild cognitive impairment or mild Alzheimer’s disease (8). More 
recently, in 2010, a scoring system was created for the memory cueing section of the 
MoCA, which previously had only been assessed qualitatively (7). This new system is 
called the Montreal Cognitive Assessment Memory Index Score (MoCA-MIS) and it 
helps determine which subjects with mild cognitive impairment are most likely to 
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transition to dementia over a follow-up period averaging 18 months. Results of a 2013 
study showed that mild cognitively impaired subjects with low MoCA and MoCA-MIS 
scores were more likely to show a rapid progression to Alzheimer’s disease (9). With 
studies validating the impact of MoCA-MIS, it was eventually added to the MoCA as 
Version 8.1 (7). 
 
Although Version 8.1 of the MoCA has been created, Version 7.1 is still widely 
used (see Appendix A for an example of MoCA Version 7.1). The MoCA has been 
translated and adapted for 46 different languages and dialects and is used in 100 
different countries. It is even offered in alternative versions to minimize any learning 
effects from multiple assessments within a timeframe of 3 months or less (7). 
 
The MoCA is divided up into 8 sections that are designed to activate a variety of 
the brain’s cognitive domains. These sections are visuospatial/executive, naming, 
memory, attention, language, abstraction, delayed recall and orientation. The 
visuospatial/executive section includes three exercises: an alternating trail-making test, 
a cube-copying test and a clock-drawing test. The alternating trail-making section 
reflects executive function and is designed to activate the frontal lobe of the brain, while 
the copying and drawing tests access visuoconstructional skills, thus stimulating both 
the parietal and occipital lobes. The naming section is a basic task that requires the test 
taker to identify and name 3 animals shown in pictures. This test stimulates the left 
hemisphere of the brain. The memory and delayed recall sections are intrinsically tied 
together. First, the test taker listens to a series of 5 words and is then asked to recall as 
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many as they can. This task is then repeated a second and third time, but on the third 
trial the examiner delays recall of the 5 words until a later time. Finally, near the 
conclusion of the assessment, the examiner asks the test taker to recall the 5 words 
that were listed earlier, but without the list being read by the examiner prior to the recall. 
Both the memory and delayed recall sections are designed to provoke the temporal lobe 
of the brain. The attention section also includes three exercises: a digit span (forward 
and backward), a vigilance task and a serial 7 subtraction test. In addition to attention, 
these tests combine to also assess concentration and calculation, which localizes brain 
activity to the frontal and left parietal lobes. The language section includes a sentence 
repetition test and a verbal fluency test. These stimulate the left hemisphere of the 
brain, but most commonly the left temporal lobe. The abstraction section uses a 
similarities test where the examiner will ask the test taker to identify features that two 
objects have in common. This type of test is designed to motivate the frontal lobe. 
Lastly, the orientation section uses some basic awareness questions during which the 
examiner may ask for the current date and time and/or the current location, arousing the 
test taker’s parietal and temporal lobes (10) (11). A general breakdown of cognitive 
function and testing by location can be examined in Figure 1. 
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Figure 1. Visual categorization of cognitive function and testing by brain location (11). 
 
The time required to administer the MoCA is roughly 10 minutes and is scored on 
a scale from 0 to 30 points. Scores of 26 and above are considered normal (12). 
Although research standards have not been established for severity levels, the 
“Frequently Asked Questions” page of the official MoCA website refers to scores of 18-
26 as indicative of mild cognitive impairment, 10-17 as moderate and anything less than 
10 as indicative of severe cognitive impairment (13).  
 
Because cognitive dysfunction has been associated with many neurological and 
systemic diseases, the MoCA has been beneficial for detecting mild cognitive 
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impairment in a diverse array of conditions such as Alzheimer’s disease, Huntington’s 
disease, Parkinson’s disease, fronto-temporal dementia, amyotrophic lateral sclerosis 
(ALS) and brain tumors, among others (7). One particular brain tumor that has not been 
explored in much depth with regard to the MoCA is the glioma. Gliomas represent 25% 
of all primary brain tumors (originating in the brain) and 75% of all those malignant, thus 
the MoCA utilized in this population could be quite impactful (14). 
 
Gliomas 
The word glioma is a general term that refers to all tumors arising from glial cells, 
a supportive tissue of the brain. Gliomas are classified by location, cell type and grade. 
Location is categorized as supratentorium, infratentorium, brainstem or spinal cord. The 
dividing boundary within the brain is a membrane known as the tentorium. Above this 
membrane is the cerebrum and below is the cerebellum and brainstem. Approximately 
70% of adult tumors originate in the cerebrum and 70% of child tumors originate in the 
cerebellum (15). A much less common location, the brainstem, accounts for only 1-2% 
of adult gliomas (16). In contrast, the brainstem accounts for a much more prevalent 10-
20% of gliomas in children (17). 
 
Gliomas can also be classified by cell type. Within this classification system, the 
three main types are astrocytoma, oligodendroglioma and ependymoma, derived from 
the three types of glial cells that can form tumors: astrocytes, oligodendrocytes and 
ependymal cells, respectively. It is also possible for tumors to display a mixture of these 
cell types in what are known as mixed gliomas or oligoastrocytomas. Three other 
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variations usually included in this classification system, but not necessarily confined to 
one particular cell type are brainstem gliomas, optic gliomas and gliomatosis cerebri 
(18). Brainstem glioma cell types are not typically specified because of the limitations of 
obtaining tissue from this location; optic gliomas are thought to be astrocytomas and 
gliomatosis cerebri is thought to be an astrocytic process. With regard to their impact on 
cognitive decline, the cell type carries less weight when compared to the location of the 
tumor and degree of infiltration. 
 
The World Health Organization (WHO) also classifies gliomas and other brain 
tumors by grade. The tumor grades range from I to IV, where a higher grade indicates a 
more advanced disease state. Grade I tumors are typically non-cancerous, slow 
growing and are associated with long-term survival. Grade II tumors are relatively slow 
growing, demonstrate atypical cell morphology and may spread to normal brain tissue 
or recur as a higher grade tumor. Grade III tumors are malignant, actively producing 
abnormal cells and invading into normal tissue; they often recur as grade IV tumors. 
Grade IV tumors are malignant, fast growing, actively produce abnormal cells, easily 
spread to normal brain tissue and often form new blood vessels to maintain such rapid 
tumor growth. Areas of necrosis in the center of grade IV tumors reflect growth that is 
outpacing the tumor’s blood supply (19). There are many factors contributing to the 
transition in grade level for these tumors, but to give a general idea of the rate of 
change, a grade II may take roughly 5-7 years to become a grade III, while a grade III 
may only take 2-3 years to convert to a grade IV. 
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Radiographic Surveillance 
High grade gliomas, grades III and IV, are the most aggressive gliomas. Because 
they grow quickly, they can severely impact the rate of cognitive decline. Consequently, 
these gliomas require the most frequent surveillance. The standard medical imaging 
technique for identifying glioma disease progression is the use of MRI, which allows 
tumors as small as 1mm to be detected. CT is also utilized in acute assessments or 
when MRI is unavailable or contraindicated. MRI is a reliable and minimally invasive 
form of radiography that has been used for decades to diagnose and stage cancers, 
along with a wide range of other applications. For individuals diagnosed with a high 
grade glioma, MRIs can be performed as frequently as every two months per standard 
of care for tumor surveillance. It is crucial to compare multiple MRIs in order to identify 
tumor growth. Although MRIs have been proven to be a safe form of radiography (if 
proper procedures are followed), they are very expensive (costs for machine use, 
interpretation by the radiologist and subsequent follow-up with a physician post- 
imaging), time consuming and can be somewhat uncomfortable for patients due to the 
loud noise and confined space. In addition, MRIs are somewhat subjective because the 
results are contingent upon the reader’s interpretation of the imaging. With regard to 
high grade gliomas, MRI results are not always definitive because the tumor infiltration 
can be at a microscopic level and below the sensitivity of the test. Consequently, 
patients can clinically deteriorate without a clear radiographic correlate that suggests 
tumor progression. Even treatment options such as the chemotherapy agent 
bevacizumab (Avastin) can alter an MRI interpretation due to substantially decreased 
contrast enhancement, which is typically abnormal in progression of high grade gliomas. 
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Unfortunately, this is currently the best method of surveillance until alternative non-
invasive substitutes for diagnosis are developed and proven to be effective. As such, 
alternative assessment measures that are able to identify tumor progression and also 
minimize the number of MRIs patients receive would be highly beneficial. 
 
Relevant Research 
A recent study by Meyers and Hess examined the cognitive deterioration of 
patients with recurrent brain tumors and suggested that a pattern of measurable brain 
function decline occurred approximately 6 weeks earlier than radiographic evidence of 
tumor progression. Figure 2 displays this pattern very nicely in the form of an event 
chart. These results would suggest that the extent of time between instances of 
radiographic surveillance is at least partially responsible for the delay in detecting 
progression, although the remaining burden likely falls on the technical limitations of 
radiographic imaging. This study used a battery of standardized psychometric tests for 
assessing a broad range of cognitive function (4). The idea of using cognitive 
deterioration as a more sensitive indicator of disease progression is an area of great 
interest for the neuro-oncology community because earlier identification of tumor 
progression could make additional treatment options available at a potentially earlier 
time point. It is hypothesized that earlier intervention could lead to improved disease 
control, but this is not yet proven. Although, the MoCA was not one of the assessment 
measures used in the Meyers and Hess study, its sensitivity and proven ability to 
identify mild cognitive impairment makes it a promising assessment tool for use in 
patients with high grade glioma. 
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Figure 2. This event chart indicates the time between the first failed psychometric test 
and radiographic evidence of tumor progression for the 56 subjects who participated in 
this trial. The subjects marked as “censored” indicate those who had not yet progressed 
(4).  
 
Research Site 
The main campus of Spectrum Health, the largest medical center in West 
Michigan, is located in downtown Grand Rapids and it has a very active neuro-oncology 
multidisciplinary clinic known as the Spectrum Health Brain and Spine Tumor Center. 
As in many other institutions, the physicians serving this facility already use MRIs 
routinely to assess disease progression for high grade glioma patients. Interestingly 
enough, one other evaluation tool that they use with this population is the MoCA. The 
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use of MoCAs was initiated in September of 2013 as a means to quantitatively measure 
the cognitive decline observed in patients with brain tumors. It was selected as the 
preferred psychometric test because it is quick, easy to administer, cost effective and 
non-invasive. Since 2013, a large collection of MoCAs has accrued, providing readily 
available data that can be compared with data from routine MRIs or the occasional CT. 
This data was used to conduct a study evaluating whether MoCAs could be adopted as 
a reliable, early identifier of high grade glioma progression. This would limit the burden 
of radiographic imaging in the high grade glioma population and provide earlier options 
for medical intervention to attempt to slow disease progression.  
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Chapter 3 Methodology 
 
Research Preparation 
In order to determine whether the sample size required for the study could be 
supported by the patient population at Spectrum Health, a preliminary report was 
executed in March of 2017 by Spectrum Health Information Services (IS) to provide a 
general idea of the current patient population numbers at this institution. High grade 
glioma diagnosis codes were used in combination with a date range dictated by the 
initiation of the MoCA as a standard assessment in the Spectrum Health Brain and 
Spine Tumor Center. As of the March 2017 report, it was estimated that 271 patients 
had a moderately high potential of meeting the study criteria. Even after taking into 
account that many potential subjects would screen fail following evaluation of all 
eligibility criteria, we anticipated that the number of eligible subjects would still be 
sufficient to achieve our goal of 128 enrolled subjects under a waiver of consent and 
Health Insurance Portability and Accountability Act (HIPAA) authorization (see 
Anticipated Statistical Analysis: Statistical Plan: Sample Size Determination). 
 
Research Approval 
A finalized research protocol was submitted to the Spectrum Health Institutional 
Review Board (IRB) for review on July 27, 2017 and later approved on August 11, 2017. 
Due to a reliance agreement in place between Spectrum Health and Grand Valley State 
University (GVSU), a second review from GVSU’s IRB was not necessary; however, 
documents reviewed and approved by Spectrum Health were filed with GVSU’s IRB and 
a formal letter was received stating that GVSU would defer research oversight to 
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Spectrum Health’s IRB. This letter was issued on August 25, 2017, giving final approval 
to begin the research. The Spectrum Health and GVSU IRB letters can be found in 
Appendix E. 
 
Recruitment Methods 
Following IRB approval, subjects were identified with the help of Spectrum 
Health’s honest broker program (an entity that has access to an entire data set and then 
distributes portions of that data to those who should not have access to the entire data 
set) in a similar fashion to how our preparatory report was generated. The honest broker 
utilized the provided variables (age, diagnosis codes, date ranges, etc.) to flag potential 
subjects, and their files were exported to a manageable list. Two additional strategies 
were used to add a few extra potential subjects to this list. The first strategy was a 
second report, built again by the honest broker program. This report was deemed to be 
more robust in its search capabilities. It was able to specifically search for any MoCAs 
documented in a certain area of the electronic medical record (EMR). Using this report, 
we identified subjects with a high grade glioma diagnosis that had at least 3 
documented MoCAs. This list was then cross referenced against the list provided by the 
first report to identify any subjects that may have been missed. The second strategy 
was to request access from the Spectrum Health IRB to utilize the screening log, 
enrollment log and database from the Glioma Data Registry for Research (IRB#: 2016-
034), an approved research project being conducted at Spectrum Health. High grade 
glioma subjects from the registry that had a known recurrence were also cross 
referenced against the list provided by the initial screen to identify any more subjects 
 29 
that were not identified previously. From there, the EMR from each individual subject on 
the list (325 total) was sequentially screened for eligibility. 
 
Inclusion and Exclusion Criteria 
The start date of the data collection window for this retrospective chart review 
was September 1, 2013, reflecting the approximate time when MoCAs were initiated 
into practice at the Spectrum Health Brain and Spine Tumor Center. The concluding 
date for the data collection window was August 11, 2017, the date of IRB approval of 
this research. 
 
Inclusion Criteria 
• Adults > 18 years of age. 
• Pathology diagnosis of a high grade glioma (WHO grade III or IV). Grade III 
pathologies included, but were not limited to, anaplastic astrocytoma, anaplastic 
oligodendroglioma and anaplastic mixed glioma (also referred to as anaplastic 
oligoastrocytoma). Grade IV pathologies included, but were not limited to, 
glioblastoma, gliosarcoma and gliomatosis cerebri. 
• Surgical resection or biopsy of high grade glioma with post-op or post-biopsy 
radiation treatment. 
• At least one instance of disease progression. 
• Completion of a minimum of three MoCAs. The baseline MoCA subsequent to high 
grade glioma resection or biopsy with post-op or post-biopsy radiation, the 
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concluding MoCA (for purposes of this study) at the first instance of disease 
progression and a minimum of one MoCA in between. 
 
Exclusion Criteria 
• Individuals < 18 years of age at the time of high grade glioma pathology diagnosis. 
• History of dementia. 
 
Setting of the Research 
The research consisted strictly of EMR data abstraction. The majority of data 
abstraction took place at the Spectrum Health Medical Center; however, approved 
mobile access to EMR software was utilized on occasion. There was no research 
interaction with any subjects because a waiver of consent and HIPAA authorization was 
granted. 
 
Resources Utilized to Conduct this Research 
For initial planning and final data analysis, we engaged the services of a 
Spectrum Health biostatistician. For recruitment purposes we accessed the Spectrum 
Health honest broker program. For screening purposes only, we used the screening log, 
enrollment log and database from the Glioma Data Registry for Research (details can 
be found under Methodology: Recruitment Methods). We also utilized Spectrum Health 
EMRs, specifically Epic and Cerner, which can be accessed anywhere on Spectrum 
Health campuses or via authorized mobile access. Other software programs such as 
OncoEMR/Virtual Integrated Patient Record (VIPR) and the Spectrum Health Cancer 
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Registry were listed in the protocol as potential resources for further medical information 
if needed, but were never used. Lastly, Research Electronic Data Capture (REDCap), a 
secure online database was chosen and operated as the depository of all data 
abstraction. 
 
Procedures Involved in the Research 
This retrospective chart review was initiated on August 25, 2017 following the 
receipt of GVSU’s IRB deferral letter. It was conducted at Spectrum Health under a 
waiver of consent and HIPAA authorization. Research data collection took 
approximately 3.5 months, followed by an additional 2 months for data analysis. It is 
expected that the study will be closed with the IRB before its approved one-year 
duration is completed.  
 
Once the research study was approved to proceed, potential subjects were 
identified with the help of the Spectrum Health honest broker program (see 
Methodology: Recruitment Methods). Each of the 325 identified potential subjects was 
individually screened for eligibility. This process involved reviewing each potential 
subject’s EMR to confirm all eligibility criteria were met. The most efficient method for 
screening the list of potential subjects was to prioritize the search by using criteria that 
would exclude a subject. In this instance, the top two criteria that eliminated potential 
subjects were the requirements that subjects must have a history of completing at least 
3 MoCAs and that they have a pathologic diagnosis of a high grade glioma. If potential 
subjects fulfilled these two requirements, a second tier of criteria were evaluated. This 
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included confirming that the potential subjects’ MoCAs occurred at the time points 
required by the protocol (baseline, intervening and progression). This process of 
elimination continued until a subject met all criteria. At that point, the subject was 
considered enrolled in the study and was assigned a unique study identification number 
to maintain confidentiality. A study correlation tool was kept securely on Spectrum 
Health’s network drive to link subjects to their study number. 
 
For enrolled subjects, retrospective data was collected from the EMR systems 
available at Spectrum Health. All data was entered and stored in a secure online 
database (REDCap) that was only accessible by IRB approved personnel. The REDCap 
project created specifically for this study was titled ‘ONC – MoCA Study’ and contained 
a series of data collection instruments built to capture all relevant data (see Appendix 
B). Once the data from all enrolled subjects was collected and entered into REDCap, it 
was exported for the ensuing statistical analysis. In addition to carrying out our planned 
statistical analysis that addressed our specific aims and secondary objectives (see 
Methodology; Anticipated Statistical Analysis), we also utilized data from our screening 
log to summarize the patient population, including any reasons for screen failure. The 
goal of this additional information was to provide a macro view of the routine use of the 
MoCA and how it aligned with our initial expectations.  
 
Anticipated Statistical Analysis 
The following information is the proposed statistical plan that established the 
foundation for the design of this research study. This information is extremely important 
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because it is crucial to understanding how we planned to address our objectives and 
answer our research questions. As a disclaimer, many research projects do not 
progress as anticipated, even if planned out exceptionally well. This particular study, 
unfortunately fell into this group. What occurred and the factors that contributed to this 
will later be explained in more detail (see Results and Discussion), but for now, having a 
clear comprehension of our precursory research strategy is essential. 
 
Statistical Plan 
Data analysis would use Statistical Analysis System (SAS) Enterprise Guide 
Version 7.1 to provide summary statistics. Quantitative data would be expressed using 
means and standard deviations, while qualitative data would be expressed using 
frequency and percentages.  
 
Primary Analysis. To test the difference in MoCA scores between baseline and 
disease progression as described in specific aim 1, we would use a parametric paired t-
test since the outcome of the MoCA score is continuous and the pre and post scores 
are dependent observations. In essence, we would take the average value of all 
patients’ baseline MoCA scores minus disease progression MoCA scores and compare 
that to zero. Then we would determine whether that difference was significant. A 
nonparametric Wilcoxon Signed Rank test was to be used if the assumption of normality 
was not met. 
 
Determining the average time point between baseline and disease progression 
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where MoCA scores show the largest magnitude of change between consecutive 
assessments would be calculated using SAS as well, but would not require a statistical 
test. Rudimentary calculations proved sufficient for achieving the result. For each 
eligible subject, the date of the MoCA that occurred between baseline and disease 
progression with the greatest magnitude of change between consecutive assessments 
would be identified. This date would be subtracted from the date of disease progression 
and the resulting number of days would then be averaged across subjects. This would 
help quantify how much earlier, in days, disease progression could potentially be 
detected by a MoCA relative to radiographic imaging. There were, however, a few 
exceptions to the rule. Any subject that had an equal magnitude of change between all 
MoCA scores (steady slope) would be excluded from the sample used to calculate 
specific aim 2. When identifying the largest magnitude of change for each subject, only 
those changes where scores were declining would be acceptable. Lastly, when 
identifying the largest magnitude of change for a particular subject, there could be 
multiple occurrences between baseline and disease progression that were equal in 
magnitude and the largest. If this were the case, the date of the MoCA with the largest 
magnitude of change from its preceding MoCA and that is closest to baseline would be 
utilized for the data point for that particular subject. 
 
Secondary Analysis. Additional statistical testing was planned for a variety of 
other demographic groupings of interest in order to identify confounding variables that 
could impact, positively or negatively, the difference in MoCA scores between baseline 
and disease progression. Distinguishing these factors could help identify demographic 
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groupings with higher possibilities of false positives/negatives affecting the reliability of 
the MoCA in early identification of disease progression. To test the average difference 
in MoCA scores between baseline and disease progression to determine whether there 
was a difference between demographic groupings, we would use a series of parametric 
two sample independent t-tests since the outcome of the difference in MoCA scores 
was continuous and the demographic groupings were all independent groups. 
Essentially, we wanted to compare two groups to see if there was a significant 
difference between them. If so, the variable would be a confounder. A nonparametric 
Wilcoxon Rank Sum test would be used if the assumption of normality was not met. The 
following is a list of the demographic groupings and how each variable was to be 
defined. 
• Age: Subjects would be divided into two age groups. Those 18-59 years of age 
and those > 60 years of age at disease progression. 
• Tumor Grade: Subjects would be divided into two groups. Those who were 
diagnosed at resection or biopsy with a WHO grade III tumor and those who 
were diagnosed at resection or biopsy with a WHO grade IV tumor. 
• Chemotherapy: Subjects would be divided into two groups. Those who were 
being treated with chemotherapy at the time of disease progression and those 
who were not being treated with chemotherapy at the time of disease 
progression. For purposes of this research study, chemotherapy is defined by the 
following medications: Temodar (temozolomide), Avastin (bevacizumab), 
Gleostine (formerly marketed as CeeNU) (lomustine), Opdivo (nivolumab), 
Keytruda (pembrolizumab), Paraplatin (carboplatin) and Camptosar (irinotecan). 
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• Stimulants: Subjects would be divided into two groups. Those who were being 
treated with stimulants at the time of disease progression and those who were 
not being treated with stimulants at the time of disease progression. For 
purposes of this research study, stimulants were defined by the following 
medications: Provigil (modafinil), Nuvigil (armodafinil), Ritalin (methylphenidate), 
Adderall (amphetamine/dextroamphetamine) and Vyvanse (lisdexamfetamine). 
• Antidepressants: Subjects would be divided into two groups. Those who were 
being treated with antidepressants at the time of disease progression and those 
who were not being treated with antidepressants at the time of disease 
progression. For purposes of this research study, antidepressants were defined 
by the following medications: Lexapro (escitalopram), Prozac (fluoxetine), Celexa 
(citalopram), Cymbalta (duloxetine), Effexor (venlafaxine) and Zoloft (sertraline). 
• Anti-Epileptic Drugs: Subjects would be divided into two groups. Those who were 
being treated with anti-epileptic drugs at the time of disease progression and 
those who were not being treated with anti-epileptic drugs at the time of disease 
progression. For purposes of this research study, anti-epileptic drugs were 
defined by the following medications: Keppra (levetiracetam), Vimpat 
(lacosamide), Lamictal (lamotrigine), Topamax (topiramate), Trileptal 
(oxcarbazepine), Tegretol (carbamazepine), Dilantin (phenytoin), Depakote 
(valproic acid) and Zonegran (zonisamide).  
 
One final area of interest would be to determine if there is a correlation between 
depression and the difference in MoCA scores between baseline and disease 
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progression. A correlation is a measure of how things are related, so understanding the 
strength and direction of this relationship, if one exists, would provide further awareness 
of the impact of depression on the reliability of the MoCA being used as an early 
identifier of disease progression. Depression would be quantified by utilizing scores 
from a routinely used depression screening tool known as the Patient Health 
Questionnaire-9 (PHQ-9; see Table 1 for the scoring interpretation and Appendix C for a 
complete example of the Spectrum Health modified version of the Pfizer Inc. 
questionnaire). The PHQ-9 score at disease progression would be used to assess 
depression. To test if there is a correlation between the depression screening tool 
scores and the difference in MoCA scores between baseline and disease progression, a 
Pearson correlation test would be used since both variables are continuous. The 
Pearson correlation test results in a value ranging anywhere from -1 to 1, where 0 
represents no correlation. A value of -1 represents a perfect negative correlation or in 
terms specific to this study, it would confirm that as depression worsens, MoCA scores 
would become more abnormal. On the other end of the spectrum, a value of 1 
represents a perfect positive correlation or in study-specific terms, a confirmation that as 
depression worsens, MoCA scores would become more normal. In effect, a very strong 
relationship in either direction would represent something similar to a confounder. It 
should not be necessary to utilize the nonparametric Spearman’s rank correlation in this 
instance.  
 
 
 
 38 
Table 1. Scoring interpretation of the PHQ-9 depression screening tool (20). 
 
 
Sample Size Determination. A sample size of 34 subjects would be required to 
accomplish our specific aims with a standard power level of 0.8; however, to test the 
additional statistical models described above at a power of 0.8 required an increase in 
that number to 128 subjects. Our study goal would be to attain 128 subjects to 
maximize our power to the standard level. If the goal of 128 subjects was not achievable 
within the parameters and constraints surrounding the conduct of the study, the 
objective would be to maximize the sample size while being sure to surpass 34 
subjects. Maximizing the sample size would consequentially elevate the power level to 
as near 0.8 as possible. Significance would be set at the standard level of 0.05. 
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Chapter 4 Results 
 
Identifying Our Study Group 
 The statistical plan that drove the study design required a sample size of 128 
subjects. Even with a list of 325 subjects with good potential, reaching this number 
seemed a bit challenging, but by no means did we foresee a final enrollment of 5. This 
was largely due to the fact that patients were not consistently receiving MoCAs at every 
office visit, which was the assumed standard of care within the Spectrum Health Brain 
and Spine Tumor Center for those individuals with a glioma. 254 of the 325 potential 
subjects did not have 3 MoCAs, a requirement under the protocol’s eligibility criteria. 
This left only 71 potential subjects having at least 3 MoCAs that still needed to be 
evaluated for secondary eligibility criteria. Of those 71 potential subjects, 30 were 
excluded because they did not have a diagnostic pathology demonstrating a high grade 
glioma. Of the final 41 potential subjects that had at least 3 MoCAs and a high grade 
glioma pathology, 36 were excluded because their MoCAs did not align with the specific 
time points described in the protocol. This also included subjects that did not 
demonstrate a recurrence within the retrospective data collection window. With the 
surprising difficulty of finding eligible subjects, we fortunately identified 5 subjects who 
did meet all study criteria and were enrolled for study specific data collection. Table 2 
details the screening breakdown. 
 
 5 enrolled subjects is quite a disparity from the 128 needed to power our 
statistical tests, so the results being shared, although tested as intended, do not have 
the statistical strength to validate the research questions we sought to answer. What it 
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does do, is help us recognize patterns that could positively change patient care within 
the Spectrum Health Brain and Spine Tumor Center and provide a foundation from 
which to build future research projects. 
  
Table 2. Screening breakdown from 325 potential subjects to 5 enrolled subjects. 
Screening group   325 
1st exclusion - Did not have ≥ 3 MoCAs - 254 
2nd exclusion - No high grade diagnosis - 30 
3rd exclusion - MoCAs do not align with protocol - 36 
Remaining (study group) = 5 
 
Screening Group Descriptive Statistics 
A more in depth look at the descriptive statistics acquired from our screening 
group exposes a more realistic look at the routine use of the MoCA within the Spectrum 
Health Brain and Spine Tumor Center. As mentioned before, we retrospectively 
screened 325 potential subjects (132 expired). Within this population, 500 total MoCAs 
were performed inside of the data collection window of September 1, 2013 to August 
11, 2017. The number of MoCAs performed per individual ranged from 0 to 13 (Table 
3). Understanding the number of MoCAs being performed at Spectrum Health under 
certain parameters was felt to be beneficial, so additional population data on tumor 
grade and pathology was captured for examination. In Tables 4 and 5, the distribution of 
potential subjects by tumor grade is displayed along with a representation of how the 
number of MoCAs (a minimum of 3) are dispersed in specifically the potential high 
grade subjects. In Table 6, the pathologies of the 325 potential subjects are listed, along 
with a count of those diagnosed and an average of the number of MoCAs conducted for 
that particular pathology. 
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Table 3. Numerical distribution of screened subjects by quantity of completed MoCAs. 
Completed MoCAs 0 1 2 3 4 5 6 7 8 9 10 11 12 13 
Number of subjects 185 43 26 18 12 12 6 7 4 6 1 0 3 2 
 
Table 4. Numerical distribution of screened subjects by WHO tumor grade. 
WHO tumor 
grade 
Number of 
subjects 
1 21 
2 42 
3 59 
4 150 
N/A 53 
 
Table 5. Numerical distribution of high grade screened subjects by quantity of 
completed MoCAs (≥ 3). 
Completed MoCAs 3 4 5 6 7 8 9 10 11 12 13 
Number of high grade subjects 11 6 6 2 5 3 5 1 0 1 1 
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Table 6. Numerical distribution of screened subjects by pathology, along with each 
group’s average number of completed MoCAs. 
Pathology Number of subjects 
Average number of 
completed MoCAs 
Anaplastic astrocytoma 43 2.4 
Anaplastic oligoastrocytoma 1 0 
Anaplastic oligodendroglioma 14 1.6 
Anaplastic pleomorphic xanthoastrocytoma 1 0 
Astrocytoma 20 1.2 
Dysembryoplastic neuroepithelial tumor 2 3 
Ependymoma 5 0.2 
Ganglioglioma 2 0 
Glioblastoma 143 1.2 
Gliomatosis cerebri 1 0 
Gliosarcoma 6 1 
Metastatic disease 16 3.5 
N/A 37 0.8 
Oligodendroglioma 18 3.4 
Pilocytic astrocytoma 14 1.4 
Subependymoma 2 1.5 
 
Study Group Descriptive Statistics 
The demographics of the study group included 4 males and 1 female, all 
identified as Caucasian. 4 of the 5 subjects were expired at the time of IRB approval. 
Glioblastoma accounted for the diagnosis of 4 of the subjects, while anaplastic 
astrocytoma accounted for just 1. The average age at the time of surgery was 55.8 ± 
22.2 years. A gross total resection was performed on 3 subjects within the group, while 
subtotal resection was performed on the other 2. MRI was the imaging technique that 
identified tumor progression for all subjects. The average time from surgery to disease 
progression was approximately 1 year (354.2 ± 63.7 days). When grouped by resection 
type, subjects with gross total resection averaged 359.7 ± 86.2 days before disease 
progression, while subject with subtotal resection averaged 346.0 ± 33.9 days. As a 
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whole, the average time from the last radiation dose to disease progression was roughly 
9 months (278.4 ± 67.9 days). 
 
Results from Specific Aim 1 
The study objectives included two specific aims. The first was to determine 
whether there was a statistically significant decline in MoCA scores from a 
predetermined baseline to disease progression. To test the difference in MoCA scores 
between baseline and disease progression as described in specific aim 1, we used a 
parametric paired t-test since the difference in MoCA scores was normally distributed. 
The test for normality used in this instance was the Shapiro-Wilk test (w = 0.96, p = 
0.81). The paired t-test, in essence, takes the average value of all patients’ baseline 
MoCA scores minus their disease progression MoCA scores and compares that to zero. 
We determined whether that difference was significantly different from zero. The 
average score of the baseline MoCA amongst the group was 25.4 ± 4.0, while the 
average score of the disease progression MoCA was 26.0 ± 4.1. Our test concluded 
that there was no statistically significant evidence to suggest a difference between the 
baseline and disease progression MoCA scores (t=-1.18, p=0.30). Although not 
significant, the negative test statistic indicates an upward trend or an improvement in 
MoCA scores at disease progression. 
 
Results from Specific Aim 2 
 The second specific aim was to determine the average time point between 
baseline and disease progression where MoCA scores demonstrate the greatest 
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magnitude of change between consecutive assessments. This was calculated using 
rudimentary calculations. Taking into account a few stipulations with regard to which 
data points would be acceptable (described in the Primary Analysis of the Statistical 
Plan), our data demonstrated a mean of 20.8 ± 29.0 days. In other words, on average, 
our study group had the largest decline in MoCA scores occur 20.8 days before 
identifying disease progression radiographically. Described with a little more detail, the 
largest decline in MoCA scores in 3 of our subjects occurred at disease progression or 
day 0. The other two subjects had their largest declining magnitude of change at 60 and 
44 days prior to disease progression, respectively. A visual representation of each 
subject’s MoCA scores by way of a line graph is displayed in Figure 3. 
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Figure 3. Line graph displaying the total score of each MoCA from baseline to disease 
progression by subject. 
 
Results from Secondary Objectives  
Our secondary analysis involved taking a hard look at a variety of demographic 
groupings in hopes to identify whether any of these were confounding variables that 
influenced the difference in MoCA scores between baseline and disease progression. 
Essentially, we were going to compare two groups to see whether there was a 
significant difference between them. If there was, then the variable would be considered 
a confounder. We planned to test this using a series of parametric two sample 
independent t-tests, however due to the size of our sample this was felt to be 
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impractical. Taking an already small group and breaking it down even further would 
likely provide nonsensical results at best and at worst the tests would just be impossible 
to run. Instead, we just captured descriptive statistics on our demographic groupings of 
interest to at least provide some understanding of our subjects. The frequency and 
percentage for each demographic grouping is displayed in Table 7. 
 
Table 7. Frequency and percentage for each demographic grouping. 
Age   
18-59 3 (60) 
≥ 60 2 (40) 
WHO tumor grade   
3 1 (20) 
4 4 (80) 
Chemotherapy at disease 
progression (On) 3 (60) 
Stimulants at disease 
progression (On) 1 (20) 
Antidepressants at disease 
progression (On) 1 (20) 
Anti-epileptic drugs at 
disease progression (On) 4 (80) 
   
 The final demographic grouping of interest that we tested as a potential 
confounding variable was depression. This variable was quantified using scores from a 
depression screening tool (PHQ-9) rather than a simple yes or no to depression as we 
had done for the other demographic groupings. We chose a Pearson correlation test for 
this particular scenario. A correlation is a measure of how two events are related, so 
essentially a very strong relationship in either direction would represent something 
similar to a confounder. In our study design, we used the PHQ-9 score at disease 
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progression as our measure of depression. 3 of our 5 subjects had a PHQ-9 score of 0 
at disease progression, which basically means they had no depression at that time. The 
other 2 had scores of 4 and 9, which are examples of higher end minimal and mild 
depression, respectively. The average or mean depression score for the sample at 
disease progression was 2.6 ± 3.97. When our data was run through our correlation 
test, we found a correlation coefficient of 0.63, which was not statistically significant due 
to our small sample size of 5. This did, however, show a trend that if disease 
progression MoCA scores are lower than baseline MoCA scores, then PHQ-9 is 
decreasing. In other words, as cognitive decline is observed through MoCAs, subjects 
also become less depressed. 
 
Additional Statistics from the Study Group 
 Finally, here are a few additional items that were captured in our statistical 
analysis to improve our overall understanding and to assist with the planning of any 
future research. We calculated the average number of intervening MoCAs for all 
subjects at 2 ± 1.2. Table 8 shows the numerical distribution by subject. We also broke 
down all the MoCAs scores and took a look at how each subject fared by cognitive 
domain. Since this was slightly complex due to a variation of maximum scores per 
domain, we instead looked at the subject’s percentage of perfect scores for each 
domain. Table 9 provides a visual of this breakdown. Lastly, the tumor locations for all 
subjects were captured to potentially breakdown domain scores by tumor location. The 
distribution of tumors by location is represented in Table 10. 
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Table 8. Number of intervening MoCAs by subject. 
Subject 
number 
Number of 
intervening 
MoCAs 
1 4 
2 2 
3 2 
4 1 
5 1 
 
Table 9. Percentage of perfect scores within each MoCA cognitive domain by subject. 
Domain Subject 1 Subject 2 Subject 3 Subject 4 Subject 5 
Visuospatial executive 0% 75% 100% 100% 67% 
Naming 83% 75% 100% 100% 100% 
Attention (list of digits) 83% 75% 100% 100% 67% 
Attention (list of letters) 100% 100% 100% 100% 100% 
Attention (serial 7 subtraction) 67% 100% 100% 33% 67% 
Language (repeat) 83% 100% 100% 100% 67% 
Language (fluency) 0% 100% 100% 100% 33% 
Abstraction 0% 50% 75% 67% 67% 
Delayed recall 0% 0% 75% 33% 0% 
Orientation 33% 75% 75% 67% 67% 
 
Table 10. Tumor location by subject. 
Subject 
number 
Left 
frontal 
Right 
frontal 
Left 
temporal 
Right 
temporal 
Left 
parietal 
Right 
parietal 
1 x   x       
2           x 
3         x   
4 x           
5   x   x     
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Chapter 5 Discussion and Conclusions 
 
Study Recap 
The goal of our study was to evaluate whether the MoCA could be adopted as a 
reliable, early identifier of high grade glioma progression. If this were proven true, in 
addition to the MoCA undoubtedly providing patients earlier options for medical 
intervention, it could also have the capacity to be used as an alternative to MRI or CT 
surveillance and limit the burden of radiographic imaging in the high grade glioma 
population. This novel concept began as a simple desire to examine the MoCA in 
conjunction with routine surveillance MRIs, however, after a thorough literature review, it 
evolved into its current state. The most influential piece of literature uncovered in that 
review was a study by Meyers and Hess examining cognitive deterioration in patients 
with recurrent brain tumors. Using a battery of standardized psychometric tests, their 
work suggested a pattern of measurable brain function decline approximately 6 weeks 
prior to radiographic evidence of tumor progression (4). In essence, Meyers and Hess 
laid the foundation for our research design. We built a comparable study focusing on 
high grade glioma patients and hoped to display similar results using the MoCA as our 
standardized psychometric test.  
 
Study Complications 
 All research is bound to have complications, even with a well thought out plan, 
and we were no different. Our study design took months to develop, and looking back, it 
is hard to see where we could have done anything differently. We moved forward with 
the information we had and conducted the study to the best of our ability. Unfortunately, 
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we ran into a pretty serious issue with regard to enrollment. Our statistical plan required 
a sample size of 34 subjects to test our primary objectives and 128 subjects for our 
secondary objectives. We had concerns from the beginning that 128 subjects might be 
difficult to obtain due to a preliminary search report that estimated that we would have 
access to only 271 subjects with a moderately high potential of meeting our eligibility 
criteria. Because of our concerns we aimed for the enrollment of 128 subjects, but left 
ourselves an escape clause within the protocol in the event our enrollment goal was not 
achievable. Our means of escape was to enroll as many subjects as feasibly possible 
beyond 34. Our hope was to test our primary objectives as intended and elevate the 
statistical power of our secondary objectives to as high of a level as possible. When all 
was said and done, our final enrollment was 5, a considerable difference from anything 
we could have imagined, even with initial concerns. 
 
 In an effort to examine this discrepancy in more detail we reviewed some of the 
data collected during the screening process. We wanted to better understand why only 
5 subjects met the study criteria of 325 solid potentials. The first step in the screening 
process was to identify the subjects with a minimum of 3 MoCAs, a study requirement. It 
was discovered that only 71 of 325 subjects met this requirement. This was an 
extremely shocking result because it was understood from conversations during the 
planning of the study that it was standard practice within the Spectrum Health Brain and 
Spine Tumor Center for all subjects with a brain tumor to have a MoCA performed along 
with every scheduled MRI. This was an expectation that the study design relied on to be 
conducted as intended and unfortunately the authenticity of that expectation could not 
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be verified at that time without an IRB approval to review patient records. Clearly, had 
we known that we would only have access to 71 potential subjects, alterations to the 
protocol would have been made at a very early stage. In addition to this damaging 
discovery, we also had to eliminate 30 subjects from the group of 71 for not having a 
high grade glioma diagnosis and 36 because their MoCAs did not align with protocol 
expectations. These last two items were not unexpected and probably wouldn’t have 
been as impressive had the original sample been receiving MoCAs as we had 
anticipated. Another surprising fact was that subjects diagnosed with a glioblastoma 
(the largest subgroup - 143 subjects) only averaged 1.2 completed MoCAs. This 
subgroup has the most severe diagnosis and in theory would seem to be the group that 
would benefit the most from completing serial MoCAs. 
 
 At the current time, we have no solid explanation for the paucity of MoCAs 
performed within the Spectrum Health Brain and Spine Tumor Center. I’m sure there 
are many factors that have contributed to this result, such as patient expiration, patient 
refusal, time constraints and untrained/unfamiliar clinic staffing, but instead of looking at 
this as a mishap or oversight, I see this as an opportunity. We can utilize the results that 
we uncovered during our screening process and share this with the neurologists who 
practice at this location. If their intention is to truly conduct MoCAs on this population as 
frequently as it was conveyed, then this information has uncovered a deficiency and 
provides a solid and validated foundation for future process improvements. 
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Anticipated Versus Actual Results 
 The final enrollment total of 5 is quite a distance from our intended sample size. 
128 enrolled subjects would have guaranteed us enough statistical power to validate 
our results as accurate. During our analysis, and when able, we tested our 5 subjects as 
intended, to learn as much as possible even though the data is not statistically 
significant. Below is our reflection on our anticipated versus actual results for our 
specific aims and secondary objectives. 
  
Based on inference from past studies and prior anecdotal evidence, we 
anticipated that specific aim 1 would show a statistically significant decline in MoCA 
scores from baseline to disease progression. We tested our 5 subjects using a 
parametric paired t-test and it concluded that there was no statistically significant 
evidence to suggest a difference between the baseline and disease progression MoCA 
scores (t=-1.18, p=0.30). The negative test statistic indicates an upward trend in MoCA 
scores at disease progression, which is the opposite of what we had predicted. We 
clearly don’t have enough subjects to trust this result, but if we had this information from 
the proper sample size (34 subjects), it would have been a clear stopping point in our 
analysis because additional aims and objectives would not have significance if there 
were no decline in cognitive function.  
 
In specific aim 2, we predicted that the average time point between baseline and 
disease progression where MoCA scores might show the greatest magnitude of change 
between consecutive assessments would be approximately 60 days prior to disease 
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progression. 60 days was chosen as the anticipated outcome due to the limitations in 
frequency of routinely administered MoCAs in the setting of this research. The 
Spectrum Health Brain and Spine Tumor Center only performs MoCAs at the time of 
radiographic imaging, thus the shortest duration between sequential imaging/MoCAs for 
routine observation of a high grade glioma is roughly 60 days. This would be the MoCA 
closest in proximity to the 6 week mark, which was proven to be the time point where 
disease progression could be identified from psychometric tests in the Meyers and Hess 
study (4). The results from our 5 subjects were calculated using rudimentary 
calculations as we had always intended and because of this we did not require any 
particular sample size. Our data demonstrated a mean of 20.8 ± 29.0 days. In other 
words, our study group on average had their largest decline in MoCA scores occur 20.8 
days before identifying disease progression radiographically. Although it was exciting to 
see a decline in MoCA scores in advance of disease progression, a standard deviation 
of ± 29.0 days really shows how widespread the data points were and does not bring 
with it a lot of confidence in this result. Nevertheless, there is still some hope that with a 
solid sample size and a significant decline in specific aim 1, seeing the largest decline in 
MoCA scores weeks in advance of disease progression could provide some treatment 
options for this population. 
 
With regard to the testing of our chosen demographic groupings, we did feel 
there was potential for us to uncover a confounding variable that would influence the 
difference in MoCA scores between baseline and disease progression. We had planned 
to use a series of parametric two sample independent t-tests, but the sample size of 5 
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was too small to break the group down even further. An intended sample size of 128 
would have not only allowed us to test for confounders, but in addition it would have 
given us the statistical strength to validate the results. Nevertheless, we were still able 
to provide descriptive statistics on these demographic groups. The frequency and 
percentage for each group is broken down in Table 6. If any of these demographic 
groupings had been tested as intended and identified as a confounder, the bulleted list 
below describes what we anticipated their influence would be on MoCA scores in either 
positive or negative directions and our justification for that prediction.  
• Age: Individuals who are advanced in age are at an increased risk for cognitive 
impairment and decline, therefore they may be more susceptible to cognitive 
decline associated with tumor progression and exhibit diminished MoCA scores. 
• Tumor Grade: Grade IV tumors are more aggressive and infiltrative than lower 
grades and as a result may be associated with considerable cognitive decline 
and inferior MoCA scores. 
• Chemotherapy: Treatment such as chemotherapy can cause fatigue and 
attentional deficits, which could negatively affect MoCA scores. 
• Stimulants: The ability of these types of medications to increase focus may 
enhance performance on MoCA testing. 
• Antidepressants: The ability of these medications to alleviate symptoms of 
depression and anxiety may improve MoCA scores (although the presence of 
depression may lead to lower scores). 
• Anti-Epileptic Drugs: Medication may cause cognitive slowing and lower MoCA 
scores. 
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Lastly, our final demographic grouping of interest that we wanted to test as a 
potential confounding variable was depression. Because depression was quantified 
using PHQ-9 scores rather than a simple yes or no to depression as we had done for 
the other demographic groupings, we had to use a Pearson correlation test. Our goal 
was to determine if there was a correlation or a very strong relationship between 
depression and the difference in MoCA scores between baseline and disease 
progression. We anticipated a negatively correlated relationship due to commonly 
known effects of depression such as low mood, anxiety and fatigue adversely 
influencing MoCA scores. Our actual result, although not statistically significant, was a 
correlation coefficient of 0.63. This demonstrated a positively correlated relationship, the 
opposite of what we had anticipated. In other words, the positive correlation coefficient 
suggests that the known effects of depression would actually favorably influence MoCA 
scores. Our outcome is a bit peculiar and we don’t have any justification for it other than 
a small sample size; However, identifying factors in this situation that would produce a 
positive correlation would make for an intriguing study.  
 
Additional Observations 
 We anticipated that we would see certain trends when examining the MoCA 
scores. One was an overall decline in MoCA scores from baseline to disease 
progression. Only 1 of our 5 subjects followed this course and the decline in MoCA 
score was a meager 1 point, so from a macro view, this seems insignificant. A second 
trend we expected to observe was that the greatest magnitude of change in MoCA 
scores (decline only) would occur somewhere in between baseline and disease 
 56 
progression, providing us some advance notice of possible progression. This occurred 
with 2 of our 5 subjects, while the other 3 demonstrated their greatest magnitude of 
change at disease progression. Because this trend was a bit more balanced, we felt as 
though examining these two groups for similarities and differences may be beneficial. 
 
 The two that demonstrated our anticipated trend were subjects #2 and #5. We 
will call this the anticipated group. The 3 who did not demonstrate what we had 
anticipated consisted of subjects #1, #3 and #4. We will identify this group as the 
unanticipated group. The anticipated group was much older at disease progression than 
the unanticipated group with average ages of 78 and 42.3, respectively. The tumor 
locations for both groups were in the frontal, temporal and parietal lobes, but what was 
interesting was that the tumor locations for the anticipated group were only on the right 
portion of the lobes and those for the unanticipated group were only on the left portion 
of lobes. We thought there might be a pattern with regard to tumor location and the 
MoCA subscores by cognitive domain, but this was not the case. We did, however, 
observe some visual patterns while investigating cognitive domain subscores (Table 9), 
but these were not fixed to our anticipated or unanticipated groups. All 5 subjects clearly 
demonstrated difficulty with the delayed recall domain, while attention (list of letters) 
was undoubtedly the most successful, as evidenced by perfect scores from all.  One 
additional item of note was that subjects #3 and #4 demonstrated very similar cognitive 
domain subscores, but this doesn’t factor well with our cross-examination by group 
because subject #1, the third piece to our unanticipated group, is clearly different. In 
addition, we see no real similarities between subjects #2 and #5, our anticipated group. 
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One last area to acknowledge was the breakdown of some of the other groups of 
interest. The anticipated group showed no similarities except for age. The unanticipated 
group, however was pretty consistent. At the time of disease progression, all 3 subjects 
were on anti-epileptic drugs, off antidepressants, off stimulants and 2 of 3 were on some 
form of chemotherapy. Although, this study delved no further into these patterns, it 
might be useful to re-examine these relationships in future studies with a larger sample. 
 
Study Limitations 
 The success of any research project depends a great deal on its design. Even 
though this sounds simple, it is actually quite complex because multiple factors 
influence a study’s design, such as the research question, objectives, population, 
funding and time. Our study design was carefully thought out, but factors existed that 
led to some limitations that repressed the power of the study.  
 
Both time constraints for the study and the short-term survival of this patient 
population led us to the decision to conduct a retrospective design, which brought about 
its own limitations. First, preliminary research preparation was limited because we could 
not examine what was in the EMR without IRB approval. Second, conducting a 
retrospective trial meant that we were at the mercy of what had been documented in the 
EMR by clinicians. In essence, there was no control over the conduct of MoCAs, 
specifically when they were performed and how consistently this was done amongst the 
population. In addition, we had no oversight of the data documentation within the EMR. 
This means that even if the data we were trying to obtain was stored in the EMR, it was 
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sometimes difficult, if not impossible to find due to individual variations in the naming 
and storage location of the data. 
 
There are other study limitations that existed as well, but didn’t play as crucial a 
part as those discussed above. In truth, we knew very well that a retrospective trial with 
time constraints would have some hurdles, but despite the circumstances, we are still 
very pleased with our study design. In fact, we believe a future variation would only 
require very slight modifications to properly test many of our objectives.   
 
Future Direction 
 Our study design is very solid and with a couple tweaks, future projects could 
easily see success. My first of two recommendations for building on our solid foundation 
would be to convert our protocol into a prospective study. This would require patient 
consent instead of the waiver of consent and HIPAA authorization we were given, but it 
would allow for greater control over the consistent use of the MoCA within the clinic 
setting, stipulating in the protocol that the MoCAs be properly completed and performed 
at time points aligning with MRI surveillance. My second recommendation would be to 
remove the secondary objectives where we were attempting to identify confounding 
variables. These are very important questions to address and would really strengthen 
the validity of the MoCA being used as an early identifier of disease progression, but 
most of these objectives required our sample size to be increased from 34 to 128 and 
this could be prohibitive in terms of budget and subject availability. A prospective 
enrollment of 34 would be much more feasible, especially for an uncommon diagnosis, 
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and enrolling 34 subjects would still be a sufficient sample size to properly test the 
specific aims. If the results were promising, extending out enrollment to 128 may seem 
more reasonable with regard to time and resources. 
 
Conclusion 
 MRI is clearly the medical community’s primary tool for identifying disease 
progression in the high grade glioma population. Finding a reliable substitute that is cost 
effective and perhaps provides advance warning is of great interest to physicians in this 
field and patients of this population, yet little research has been done to identify an 
alternative. Building from ideas in previous research, we designed a study to assess 
whether or not the MoCA, a cognitive assessment tool, could be identified as a reliable 
early identifier of disease progression in this population.  
 
Our results were not able to support the MoCA as a reliable and early identifier of 
disease progression as we had hypothesized, mainly due to our small sample. Our 
difficulty enrolling our intended sample size greatly impacted our statistical tests, leaving 
the majority of our results insignificant. What we learned from our sample was that 
MoCA scores actually improved from baseline to disease progression. A recent study 
examining neurocognitive function in patients with glioblastoma demonstrated evidence 
of neurocognitive decline at the time of progression in patients with investigator-
determined progressive disease (21). Our outcome is considerably different from what 
similar research has shown. We also identified that our study group on average had 
their largest decline in MoCA scores 20.8 days before identifying disease progression 
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radiographically. This is definitely an encouraging result because there is potential for 
identifying progression in advance of an MRI. Lastly, we identified a positive correlation 
between depression and the difference in MoCA scores between baseline and disease 
progression, which suggests that the known effects of depression favorably influence 
MoCA scores. This is quite the contrary to most research on depression and cognitive 
function. A 2011 article analyzing observational studies that examined depression in 
patients with glioma found that depression was consistently associated with cognitive 
dysfunction (22).  
 
Even with enrollment difficulty and some unexpected outcomes, our research 
contributed a solid study design and identified some interesting areas for exploration. 
We definitely feel the MoCA has potential to address our hypothesis. Hopefully, this 
study will provide a basis for a more thorough investigation of the MoCA and its use as 
an early and reliable identifier of disease progression in the high grade glioma 
population.  
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Appendix A 
 
• Montreal Cognitive Assessment version 7.1 (original version).  
• Montreal Cognitive Assessment version 7.2 (alternate version). 
• Montreal Cognitive Assessment version 7.3 (alternate version) (12). 
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Appendix B 
 
• REDCap data collection tool dated 08/30/2017 (23). 
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Appendix C 
 
• Spectrum Health modified version of Pfizer Inc.’s Patient Health Questionnaire-9. 
Unaltered versions are publically available online (20). 
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Appendix D 
 
• Protocol version date July 27, 2017. 
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Appendix E 
 
• Spectrum Health IRB approval letter dated August 11, 2017 (initial submission). 
• GVSU IRB deferral letter dated August 25, 2017. 
• Spectrum Health IRB approval letter dated September 8, 2017 (modification). 
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